Document Detail

Altered kinetics of interleukin-6 and other inflammatory mediators during exercise in children with type 1 diabetes.
MedLine Citation:
PMID:  18382266     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Leukocyte mobilization and secretions of cytokines, chemokines, and growth factors in children during exercise are necessary biochemical signals for physiological growth and long-term cardiovascular protection. Because of glycemic instability, altered exercise responses, particularly the proinflammatory cytokine interleukin (IL)-6, may occur in type 1 diabetes mellitus (T1DM) that could influence the onset/progression of diabetic vascular complications. Relatively little is known, however, on most molecular aspects of immunomodulatory adaptation to exercise in diabetic children.
METHODS: We therefore studied 21 children (age, 13.4 +/- 0.3 years; 13 boys/8 girls) with T1DM and 21 age-matched healthy controls during 30 minutes of intense and intermittent cycling exercise. Euglycemia was maintained during and for greater than 90 minutes before exercise; blood samples for IL-6 and other cytokines/chemokines were drawn before, during (every 6 minutes), and after (every 15 minutes) exercise.
RESULTS: In T1DM, exercise-induced IL-6 peak occurred earlier and with greater magnitude than that in controls; an exploratory analysis of additional inflammatory mediators displayed a similarly accelerated/exaggerated pattern in T1DM, including the kinetic profiles of tumor necrosis factor alpha, IL-4, IL-12p70, IL-17, granulocyte-monocyte colony-stimulating factor, monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha, and eotaxin (interferon-inducible protein-10 was the only measured variable essentially indistinguishable between groups).
CONCLUSION: Therefore, during intense and intermittent exercise, significant alterations in the immunologic pattern of inflammatory regulation occurred in children with T1DM as compared with healthy controls. Our findings underscore how the understanding of all the underlying molecular mechanisms is a necessary prerequisite for achieving effective use of exercise and the full manifestation of its health benefits, particularly in understudied populations such as children with T1DM who are at increased risk for cardiovascular complications.
Jaime S Rosa; Stacy R Oliver; Masato Mitsuhashi; Rebecca L Flores; Andria M Pontello; Frank P Zaldivar; Pietro R Galassetti
Related Documents :
25121516 - Distance-dependent association of affect with pacing strategy in cycling time trials.
23325716 - Prior exercise reduces fast-start duration and end-spurt magnitude during cycling time-...
10893016 - Low-dose budesonide improves exercise-induced bronchospasm in schoolchildren.
21221986 - Treadmill training prevents bone loss by inhibition of pparγ expression but not promot...
21815126 - Effect of exercise on vascular superoxide dismutase expression in high-risk pregnancy.
19693626 - Association of exercise capacity and the heart rate profile during exercise stress test...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of investigative medicine : the official publication of the American Federation for Clinical Research     Volume:  56     ISSN:  1081-5589     ISO Abbreviation:  J. Investig. Med.     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-04-02     Completed Date:  2008-12-09     Revised Date:  2013-06-07    
Medline Journal Info:
Nlm Unique ID:  9501229     Medline TA:  J Investig Med     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  701-13     Citation Subset:  IM    
Department of Pediatrics, Institute for Clinical Translational Science, School of Medicine, University of California, Irvine, CA 92612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / analysis
Diabetes Mellitus, Type 1 / immunology*
Inflammation Mediators / blood*
Interleukin-6 / blood*,  genetics
Leukocytes / metabolism
Grant Support
K-23 RR18661-01/RR/NCRR NIH HHS; M01 RR000827/RR/NCRR NIH HHS; M01-RR00827-28/RR/NCRR NIH HHS; UL1 TR000153/TR/NCATS NIH HHS
Reg. No./Substance:
0/Blood Glucose; 0/Inflammation Mediators; 0/Interleukin-6

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clopidogrel use in coronary heart disease and percutaneous coronary intervention.
Next Document:  Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE i...